Murine models are increasingly used for investigations of sleep, yet no previous studies have characterized cholinergic activation of guanine nucleotide binding proteins (G proteins) in mouse brainstem nuclei known to regulate sleep. This study used in vitro
Most human genes have a mouse homologue (O'Brien et al., 1999) . This homology encourages identification of mouse genes influencing disease susceptibility and can point to polymorphisms relevant to human disease (Paigen and Eppig, 2000) . Linking successes in mouse genomics to integrative neuroscience will require parallel progress with proteomic and behavioral phenotyping of mouse (Paigen and Eppig, 2000) . Phenotyping mouse strains is important for developing a mouse database that can be compared with other species. Much of the current progress in neuroscience has come from studies of rat. The present results provide the first quantitative comparison of guanine nucleotide binding proteins (G proteins) in brainstem of rat and mouse. In accord with recommendations of The Jackson Laboratory's Mouse Phenome Project, this study used the C57BL/6J (B6) mouse, as a strain from which original phenotyping data are needed (Paigen and Eppig, 2000) .
There is good agreement between many laboratories that brainstem cholinergic neurotransmission contributes to sleep cycle control (Aldrich, 1999; Lydic and Baghdoyan, 1999; Kryger et al., 2000) . Directly administering cholinergic agonists or acetylcholinesterase inhibitors into the medial part of cat pontine reticular formation (mPRF) or the homologous pontine reticular nucleus, oral part (PnO) of rat causes a concentration-dependent enhancement of rapid eye movement (REM) sleep (reviewed in Baghdoyan and Lydic, 2002) . Acetylcholine (ACh) release in feline mPRF is significantly greater during REM sleep than during non-REM sleep and wakefulness (Leonard and Lydic, 1997) . Cholinergic agonists increase REM sleep by means of muscarinic cholinergic receptors (mAChRs) coupled to pertussis toxin-sensitive G proteins (Shuman et al., 1995) . The mAChRs modulating REM sleep are likely to be postsynaptic and of the M2 subtype . Recent studies of intact, unanesthetized mice show for the first time that a REM sleep-like state is caused by microinjection of neostigmine into the PnO of B6 mouse . Neostigmine prevents the enzymatic degradation of ACh. Thus, the ability to cholinergically enhance REM sleep in B6 mouse is consistent with in vivo microdialysis data showing that endogenously released ACh can be measured in PnO of B6 mouse (Coleman et al., 2001 (Coleman et al., , 2002 .
Cholinergic transmission in brainstem also plays a role in antinociception. Microinjection of cholinomimetics into the mPRF of cat (Kshatri et al., 1998) and PnO of rat (Ishizawa et al., 2000) produces antinociceptive behavior. In rat PnO, the M2 muscarinic receptor subtype has been suggested to modulate antinociceptive behavior . The mesencephalic periaqueductal gray (PAG) is a brainstem area known to modulate sleep (Sastre et al., 1996) and nociception (Reynolds, 1969; Besson and Chaouch, 1987) . Microinjection of cholinergic agonists into sites throughout the PAG produces antinociceptive behavior (Klamt and Prado, 1991) .
The foregoing findings support the view that cell surface mAChRs and their associated G proteins may be regarded as a lower level phenotype that modulates higher level phenotypes such as REM sleep and nociception. No previous studies have characterized cholinergic activation of G proteins in mouse brainstem. Therefore, the present study used in vitro autoradiography to test the hypothesis that carbachol activates G proteins in the brainstem of B6 mouse. Activated G proteins were assayed by using (Sim et al., 1995 (Sim et al., , 1997 . Seven brainstem nuclei, known in other mammals to regulate sleep and nociception, were selected for quantitative analysis of G protein activation. Portions of these data have been presented in abstract form (DeMarco et al., 2001 ).
MATERIALS AND METHODS

Animals and chemicals
Male B6 mice (22-24 g) were purchased from The Jackson Laboratory (Bar Harbor, ME). NEN Life Science Products (Boston, MA) was the source for [
35 S]GTP␥S (1,250 Ci/mmol) and Kodak X-OMAT Blue XB-1 autoradiography film. Sigma Chemical Co. (St. Louis, MO) supplied unlabeled guanosine 5Ј-(␥-thio) triphosphate (GTP␥S), guanosine 5Ј-diphosphate (GDP), carbachol, and atropine sulfate.
Preparation of tissue sections
All procedures involving animals were approved by the University of Michigan Committee on Use and Care of Animals and conducted in accordance with the Public Health Service policy on Humane Care and Use of Laboratory Animals (NIH Publication 80-23). Mice were kept on a 12-hour light/dark cycle with lights on at 6:00 AM and were decapitated between 9:30 AM and 11:00 AM. Brains were removed and frozen in a Ϫ30°C bilayer of isopentane and bromobutane. Serial, 20-m coronal sections cut on a Hacker Bright OTF cryostat (Fairfield, NJ) were thawmounted onto gelatin-coated glass slides with one pair of adjacent sections per slide. Tissue sections were dried for 2 hours in a cold (5-8°C) vacuum desiccator, then stored at Ϫ80°C.
In vitro autoradiography for carbacholactivated G proteins
The [ 35 S]GTP␥S binding assay was performed as previously described (Sim et al., 1995 (Sim et al., , 1997 . Brainstem sections from a total of 11 mice were sorted sequentially to ensure that for all mice, each brain region was treated with every binding condition. Tissue sections were soaked in assay buffer (50 mM Tris-HCl, 3 mM MgCl 2 , 100 mM NaCl, and 0.2 mM ethylene glycol tetraacetic acid, pH 7.4 ) for 10 minutes, and preincubated in the same buffer containing 2 mM GDP for 15 minutes. Brainstem sections then were incubated for 2 hours in a binding bath composed of assay buffer (pH 7.4) containing 0.04 nM [ 35 S]GTP␥S and 2 mM GDP. Tissue sections from eight mice were treated with either the cholinergic agonist carbachol (1 mM) or carbachol plus the muscarinic antagonist atropine (0.1 mM). Brainstem sections from three mice were incubated with one of four concentrations of carbachol: 1 ϫ 10 Ϫ7 M, 1 ϫ 10 Ϫ5 M, 1 ϫ 10 Ϫ3 M, and 1 ϫ 10 Ϫ2 M. Basal G protein activation was assayed by incubating tissue sections without carbachol or atropine. Nonspecific binding (NSB) was determined by incubation with 10 M unlabeled GTP␥S in the absence of carbachol or atropine. After the incubation period, tissue sections were rinsed twice with ice-cold Tris buffer (pH 7.0) for 2 minutes and once in ice-cold deionized H 2 O for 30 seconds. Tissue sections were dried at room temperature, first with a stream of forced air and then in a vacuum desiccator overnight. Dry tissue sections were placed in stainless steel film cassettes with 14 C Microscale standards (Amersham, Arlington Heights, IL; 31-883 nCi/g) and autoradiography film. Seventy-two hours later, films were developed by using a Kodak X-OMAT-2000A autoprocessor. Hot (80°C) paraformaldehyde vapor was used to fix the tissue sections (Herkenham and Pert, 1982) , which were then stained with cresyl violet.
Data collection and analysis
A Northern Light illuminator (Imaging Research, Ontario, Canada) was used to backlight cresyl violet-stained tissue sections and the corresponding autoradiograms. Stained sections and autoradiographic films were digitized by using a Cohu (San Diego, CA) CCD camera connected to an Apple G3 computer by means of a digitizing card (Data Translations, Marlboro, MA). The Scion Image (1.62c) program was used to quantify G protein activation by densitometric analysis of the digitized autoradiograms. Figure 1 shows autoradiograms from rat and mouse brainstem sections treated with carbachol (1 mM). These im-ages illustrate the ability to resolve specific reticular fields and nuclei. The seven brainstem nuclei studied were dorsomedial periaqueductal gray (DMPAG), dorsal raphe nucleus (DR), pedunculopontine tegmental nucleus (PPT), pontine reticular nucleus (caudal part, PnC), pontine reticular nucleus (oral part, PnO), laterodorsal tegmental nucleus (LDT), and ventrolateral periaqueductal gray (VLPAG). Mouse brainstem nuclei were localized on the cresyl violet-stained sections according to the mouse brain atlas (Franklin and Paxinos, 1997) . Rat PAG nuclei were localized according to the rat brain atlas (Paxinos and Watson, 1999) . The anatomic limits of each nucleus were outlined on the digitized, cresyl violet-stained section. The outline then was superimposed onto the corresponding autoradiographic image to ensure accurate localization of each nucleus. Optical density measurements of total binding were obtained from each tissue section.
Specific [
35 S]GTP␥S binding values were calculated by subtracting mean NSB values for each brainstem nucleus from the total binding values for that nucleus.
Data from mouse were analyzed by a mixed effects model analysis of variance (ANOVA) for repeated measures and post hoc Tukey's multiple comparison test (P Ͻ 0.05) using SAS (release 8.8, SAS Institute, Inc., Cary, NC). The numerator degrees of freedom (df) equals the number of conditions minus 1, and the denominator degrees of freedom equals the numerator df multiplied by the number of animals used per nuclei minus 1. In instances where unequal numbers of animals were used, the SAS program decreases the degrees of freedom accordingly. Data from rat PAG were collected previously (Capece et al., 1998a) and analyzed for the present study by ANOVA. For both rat and mouse, the number of measurements obtained for a given nucleus depended on the Relative to bregma in the rat atlas (Paxinos and Watson, 1999) , A corresponds to Ϫ9.30 and B to Ϫ7.64. Relative to bregma in the mouse atlas (Franklin and Paxinos, 1997) , C corresponds to Ϫ5.40 and D to Ϫ4.48. Scale bar ϭ 1 mm.
anterior-to-posterior extent of the nucleus and whether or not the nucleus was bilaterally symmetrical. For example, because mouse PnC spans from bregma Ϫ5.02 to Ϫ5.68 and is bilaterally symmetrical, the quantitative data included approximately 12 measurements per mouse per treatment condition. For mouse DR, which ranges from bregma Ϫ4.04 to Ϫ4.36 and is a midline structure, measurements consisted of approximately five values per mouse per treatment condition.
RESULTS
Figure 2 uses color-coded images of autoradiograms to illustrate total [
35 S]GTP␥S binding. Basal levels of [ 35 S]GTP␥S binding were relatively low and heterogeneous (Fig. 2, top row) . Carbachol (1 mM) activated G proteins throughout the brainstem (Fig. 2, middle row) , and atropine blocked carbachol-stimulated [
35 S]GTP␥S binding (Fig. 2, bottom row) . The images in Figure 2 are from a single mouse and are representative of the group data. Figure 3A quantifies specific [ 35 S]GTP␥S binding in seven nuclei of mouse brainstem. For all nuclei studied, carbachol (1 mM) significantly increased G protein activation above basal levels, and atropine (0.1 mM) reduced carbachol-stimulated G protein activity to basal levels. The Figure 3A data represent 1,049 measurements from eight mice for VLPAG, DMPAG, DR, PnO, and PnC, 155 measurements from six mice for PPT, and 124 measurements from four mice for LDT. Power analysis indicated that four animals yielded a sufficient sample size for statistical analysis of LDT. ANOVA revealed a significant effect of treatment condition in VLPAG (F (2,14) ϭ 65.02; P Ͻ 0.001), DMPAG (F (2,14) ϭ 80.2; P Ͻ 0.001), DR (F (2,14) ϭ 137.14; P Ͻ 0.001), LDT (F (2,6) ϭ 74.9; P Ͻ 0.001), PPT (F (2,10) ϭ 63.5; P Ͻ 0.001), PnO (F (2, 14) ϭ 121.43; P Ͻ 0.001), and PnC (F (2,14) ϭ 71.47; P Ͻ 0.001).
Although sleep-related brainstem nuclei have been studied in rat with respect to cholinergic activation of G proteins (Capece et al., 1998a) , no previous studies have demonstrated cholinergic activation of G proteins in rat PAG. Figure 3B illustrates G protein activation quantified for DMPAG and VLPAG of rat. These data represent 264 measurements from six rats. Carbachol (1 mM) significantly increased specific [
35 S]GTP␥S binding in DMPAG (F (2,15) ϭ 14.7; P Ͻ 0.001) and VLPAG (F (2,15) ϭ 19.2; P Ͻ 0.001). Atropine (0.1 mM) returned carbachol-stimulated [ 35 S]GTP␥S binding to basal levels.
This study next sought to determine whether carbachol-induced G protein activation was concentrationdependent and could be saturated. The autoradiograms in Figure 4A demonstrate the concentration response for carbachol-stimulated [
35 S]GTP␥S binding in mouse brainstem. Increases in [
35 S]GTP␥S binding corresponding to G protein activation are apparent at carbachol concentrations greater than 1 ϫ 10 Ϫ7 M. These images are representative of those used to obtain quantitative concentration-response data. Figure 4B Ϫ7 M. Figure 5A shows that, in mouse brainstem, carbachol-induced [
35 S]GTP␥S binding was concentrationdependent and could be saturated. Due to the small size of the mouse brainstem and the need to test each concentration of carbachol in tissue sections from the same mouse, two brainstem regions with relatively long rostral-tocaudal extents were selected for concentration-response analysis. These were the pontine reticular formation (PRF) and the PAG. The PRF was defined to include PnO and PnC, and the PAG was defined to include VLPAG and DMPAG. The Figure 3A data showed that there was no significant difference in [ 35 S]GTP␥S binding between PnO and PnC for any treatment condition, providing a rationale for combining measures from these nuclei. Similarly, there was no difference in G protein activation between VLPAG and DMPAG (Fig. 3A) , and measures from these two areas were combined for the concentration-response analysis. The Figure 5A data summarize 376 measurements obtained from three mice. ANOVA revealed a significant effect of carbachol concentration in PRF (F (4,8) (Fig. 3B) . Therefore, Figure  5B combines measures from VLPAG and DMPAG as a function of carbachol concentration. The Figure 5B data were obtained from 339 measurements in three rat brains. ANOVA revealed a significant effect of carbachol concentration on [ 35 S]GTP␥S binding in PAG. G protein activation by 1 mM carbachol was significantly greater than basal values. Figure 6 compares carbachol-stimulated G protein activation as a percentage of basal [
35 S]GTP␥S binding between mouse and rat for five brainstem regions. ANOVA indicated a statistically significant region main effect for carbachol-stimulated [
35 S]GTP␥S binding in mouse (F (6,36) ϭ 63.86; P Ͻ 0.0001) and rat (F (6,30) ϭ 142.9; P Ͻ 0.0001). The greatest increase over basal [
35 S]GTP␥S binding was in PRF (105%) for mouse and LDT (75%) for rat. The lowest percentage increase over basal binding was found in DR and PAG (53%) for mouse and PAG (43%) for rat. Student's t-test revealed statistically significant differences in G protein activation between mouse PRF and rat PRF.
DISCUSSION
The present data demonstrate, for the first time, cholinergically mediated G protein activation in brainstem nuclei of B6 mouse. Stimulation of G proteins by carbachol was heterogeneous across nuclei, concentrationdependent, and blocked by atropine. This study also provides the first comparison of cholinergically induced G protein activation between specific brainstem nuclei of mouse and rat. Data were obtained by using in vitro 
Carbachol-stimulated [
S]GTP␥S binding in mouse and rat brainstem was mediated by muscarinic cholinergic receptors
Two criteria must be met to demonstrate that a process is receptor mediated. One is the blocking of ligand action by a receptor antagonist. The second criterion is a concentration-response that saturates. The present data satisfy both criteria.
Atropine is a competitive inhibitor of mAChRs, and atropine blocked carbachol-stimulated G protein activation in mouse (Figs. 2, 3A) and rat (Fig. 3B) . This finding supports the conclusion that carbachol-induced G protein activation in mouse brainstem and rat PAG is mediated by mAChRs. The present G protein data are congruent with data showing that atropine blocks carbachol-stimulated [ 35 S]GTP␥S binding in cortical membranes from human brain (Gonzalez-Maeso et al., 2000) and in REM sleeprelated brainstem nuclei of rat (Capece et al., 1998b) . The present results are consistent with in vivo data demonstrating that muscarinic antagonists inhibit cholinergically induced REM sleep in cat (Baghdoyan et al., 1984; Velazquez-Moctezuma et al., 1990; Baghdoyan and Lydic, 1999) and rat (Imeri et al., 1994; Bourgin et al., 1995) .
G protein activation was concentration-dependent in mouse pontine reticular formation and mouse and rat periaqueductal gray (Fig. 5) . The concentration-response curves for PRF and PAG also exhibited saturation, consistent with a receptor mediated process. These findings parallel previously reported concentration-response curves for carbachol-stimulated [
35 S]GTP␥S binding in chick optic tectum (Kurkinen et al., 1997) and rat PRF (Capece et al., 1998a) . Studies microinjecting cholinomimetics into the PRF in vivo have demonstrated the concentration-dependent nature of cholinergically enhanced REM sleep in cat (Baghdoyan et al., 1984 (Baghdoyan et al., , 1989 and rat (Bourgin et al., 1995) .
Comparison of carbachol-stimulated G protein activation in rat and mouse brainstem
Activation of G proteins by carbachol was not significantly different between the PnC and PnO regions of mouse pontine reticular formation (Fig. 3A) . In mouse (Fig. 3A) and rat (Fig. 3B) , G protein activation was not different between the DMPAG and VLPAG regions of the periaqueductal gray. In both mouse and rat, activation of G proteins by carbachol was heterogeneous across the other nuclei studied. In mouse, the largest percentage change from basal activation was noted in the PRF, whereas in rat, the largest change was noted in the LDT (Fig. 6) . The lowest percentage change from basal activation for both species was seen in DR and PAG. These findings are consistent with other comparative studies of mouse and rat. For example, the distribution of galaninergic immunoreactivity in mouse brain is similar to that of rat in most areas but is significantly different in the olfactory bulb, thalamus, pretectum, and medulla (Perez et al., 2001) . Cholinergic innervation as measured by choline acetyltransferase activity is similar in mouse and rat corpus striatum, thalamus, basal forebrain, and pons, but significantly different in the neocortex (Owasoyo and Olowookorun, 1982; Gordon and Finch, 1984; Kitt et al., 1994) . Statistically significant differences were noted between carbachol-stimulated [
35 S]GTP␥S binding in mouse and rat PRF (Fig. 6 ).
Functional implications
Carbachol was chosen as the agonist to activate receptor-coupled G proteins because of the good consensus that brainstem ACh significantly modulates electroencephalographic and behavioral arousal Baghdoyan, 1998, 1999; Aldrich, 1999; Kryger et al., 2000) . The present functional neuroanatomic data can be related to in vivo pharmacologic data regarding the cholinergic modulation of REM sleep. Microinjection of cholinomimetics into feline PRF regions homologous to mouse PRF causes REM sleep to increase by several hundred percent . Similar microinjections into homologous PRF regions of rat either failed to consistently Quantitative analysis revealed that, in mouse, carbachol caused G protein activation, and atropine blocked the carbachol-induced activation in each of the seven nuclei studied. These data demonstrate that G protein activation was mediated by muscarinic receptors. Asterisks indicate significant increases in G protein activation over respective basal and carbachol ϩ atropine levels (P Ͻ 0.0001). B: Carbachol activated G proteins in rat dorsomedial (DMPAG) and ventrolateral (VLPAG) periaqueductal gray. Carbachol activation of G proteins was blocked by atropine, indicating mediation by muscarinic cholinergic receptors. Asterisks indicate significant increases in G protein activation over respective basal and carbachol ϩ atropine levels (P Ͻ 0.01). (Franklin and Paxinos, 1997) . B: Sequential coronal sections from the same rat brainstem span from bregma Ϫ8.00 (top) to Ϫ7.64 (bottom; Paxinos and Watson, 1999) . Scale bar ϭ 1 mm.
increase REM sleep (Deurveilher et al., 1997) or increased REM sleep by approximately 50% (Bourgin et al., 1995) . Thus, there are important species differences between cat and rat with respect to cholinergic triggering of REM sleep.
Microinjection data from rat also indicate that cholinergic stimulation of PnC is significantly less efficacious in causing REM sleep enhancement than cholinergic stimulation of PnO (Bourgin et al., 1995) . These functional data can be contrasted with the observations of no significant difference in cholinergic activation of G proteins between PnO and PnC of mouse (Fig. 3A) or rat (Capece et al., 1998a) . Similarly, there is a homogeneous distribution of mAChRs across PnO and PnC of rat (Baghdoyan, 1997) . Thus, the REM sleep-enhancing actions of carbachol are significantly greater in rat PnO than PnC (Bourgin et al., 1995) in the absence of significant differences between PnO and PnC in density of mAChRs (Baghdoyan, 1997) or cholinergically activated G proteins (Capece et al., 1998a) . Figure 6 shows that the same concentration of carbachol caused significantly greater G protein activation in mouse PRF than in rat PRF. One function of G proteins is amplification of transmembrane signaling, and the Figure 6 data suggest that REM sleep in mouse also will be increased by pontine administration of cholinomimetics. This implication is supported by three new findings. First, PnO microinjection of the acetylcholinesterase inhibitor neostigmine causes REM sleep enhancement in B6 mouse . Second, the cholinergic agonist carbachol also increases REM sleep when microinjected into PnO of B6 mouse (Fig. 7) . Third, microdialysis data show that endogenous ACh is released in PnO of B6 mouse (Coleman et al., 2001 (Coleman et al., , 2002 .
In rat periaqueductal gray, microinjection of carbachol causes antinociception (Guimaraes et al., 2000) . The present data show that, in mouse and rat periaqueductal gray, G proteins were activated by carbachol (Figs. 2, 3, 5) . Considered together, these data suggest that microinjection of cholinergic agonists into periaqueductal gray of B6 mouse will cause antinociception. This speculation is open to future investigation.
Limitations and conclusions
The [ ]GTP␥S) binding in mouse and rat brainstem. G protein activation by 1 mM carbachol was heterogeneous across nuclei in both mouse and rat. G protein activation was significantly greater in mouse pontine reticular formation (PRF) than in rat PRF (*P Ͻ 0.05). Rat data for PRF, pedunculopontine tegmental nucleus (PPT), laterodorsal tegmental nucleus (LDT), and dorsal raphe nucleus (DR) are from (Capece et al., 1998a) .
[ 35 S]GTP␥S assay have been discussed previously (Sim et al., 1995 (Sim et al., , 1997 , it should be noted in the context of the present study that the assay does not resolve the specific subtypes of activated G proteins. The assay has been suggested to favor activation of inhibitory G proteins (Kurkinen et al., 1997) . In addition, in vitro stimulation of G proteins by carbachol may not parallel in vivo activation of G proteins by ACh.
In conclusion, this study is the first to quantify cholinergically activated G proteins in brainstem nuclei of B6 mouse that are known to regulate sleep-induced alterations in arousal and nociception. The present results also provide the first comparison of cholinergically activated G proteins in rat and mouse brainstem. These comparative data are in agreement with data demonstrating that cholinergically activated [ 35 S]GTP␥S binding is concentration-dependent and blocked by muscarinic antagonists (Kurkinen et al., 1997; Capece et al., 1998a) . Sleep is a heritable phenotype in humans (Katzenberg et al., 1998; Toh et al., 2001) , and sleep varies significantly as a function of mouse strain (Franken et al., 1998; Huber et al., 2000) . Applying the power of mouse genetics to sleep neurobiology will require establishing causal links between genes regulating lower level phenotypes such as G proteins and higher level phenotypes such as sleep. Microinjection of carbachol caused nine epochs of the REM sleep-like state (REM Carb ) comprising 51.1% of the 60-minute recording. Non-REM sleep (NREM) was eliminated in the first hour after carbachol microinjection. REM sleep enhancement by carbachol is consistent with data from eight B6 mice, showing that microinjection of neostigmine into the oral part of the pontine reticular nucleus causes a REM sleep-like state .
NREM
